FDA Approves New Use of SPRAVATO™ (esketamine) for Major Depressive Disorder and Acute Suicidal Behavior
The U.S. Food and Drug Administration (FDA) has approved a new medication for people suffering from depression and acute suicidal behavior — SPRAVATO™. This medication was originally approved only for treatment-resistant depression, though it can now be used for acute suicidal ideation or behavior without treatment-resistant depression. This change is due to its effectiveness in reducing depressive symptoms and suicidal thoughts.…